Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Artgen Biotech PJSC's Enterprise Value is ₽6,192 Mil.
Artgen Biotech PJSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₽125 Mil. Therefore, Artgen Biotech PJSC's EV-to-EBIT ratio for today is 49.39.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Artgen Biotech PJSC's Enterprise Value is ₽6,192 Mil.
Artgen Biotech PJSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was ₽188 Mil. Therefore, Artgen Biotech PJSC's EV-to-EBITDA ratio for today is 32.85.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Artgen Biotech PJSC's Enterprise Value is ₽6,192 Mil.
Artgen Biotech PJSC's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was ₽1,238 Mil. Therefore, Artgen Biotech PJSC's EV-to-Revenue ratio for today is 5.00.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Artgen Biotech PJSC (MIC:ABIO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₽125 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was ₽188 Mil.
Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was ₽1,238 Mil.
Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 was ₽225 Mil.
Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was ₽121 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artgen Biotech PJSC Enterprise Value Related Terms
Artgen Biotech PJSC Enterprise Value Historical Data
* Premium members only.
The historical data trend for Artgen Biotech PJSC's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIC:ABIO vs VRTX, REGN, SGEN: Enterprise Value Comparison
For the Biotechnology subindustry, Artgen Biotech PJSC's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artgen Biotech PJSC Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Artgen Biotech PJSC's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Artgen Biotech PJSC's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artgen Biotech PJSC (MIC:ABIO) has a Enterprise Value of ₽6,192 Mil as of Aug. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Enterprise Value too high?
Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Enterprise Value compare to VRTX and REGN?
Artgen Biotech PJSC's Enterprise Value of ₽6,192 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Enterprise Value of ₽6,192 Mil. The current Enterprise Value is ₽6,192 Mil. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Enterprise Value is ₽6,192 Mil as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score
Get the complete analysis for MIC:ABIO
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIC:ABIO has been successfully added to your 
